Insider trade

Johnson & Johnson (JNJ): Director received 75.26 units

Marillyn A Hewson, Director at Johnson & Johnson, reported a grant / award of 75.26 units.

75.26
Derivative units · @ $166.10
Traded
Mar 4, 2025
Filed
Mar 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 6, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Dec 10, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  3. Dec 12, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  4. Dec 31, 2024CongressDisclosed sale of JNJ — reported range $100,001 - $250,000
  5. Jan 8, 2025Congress · 1 personMembers of Congress: 4 purchases
  6. Jan 16, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  7. Jan 21, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  8. Jan 24, 2025Congress · 2 peopleMembers of Congress: 1 purchase, 1 sale
  9. Feb 7, 2025InsiderCFO sold ~$2M of JNJ shares in the open market
  10. Feb 18, 2025InsiderChair sold ~$63K of JNJ shares in the open market
  11. Feb 24, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  12. Feb 25, 2025InsiderOfficer sold ~$1.16M of JNJ shares in the open market
  13. Mar 3, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  14. Mar 4, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000

What came next

  1. Mar 5, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  2. Mar 7, 2025FDARecall: PDS¿PLUS¿VIO¿30IN(75CM)¿USP6-0(M0.7)¿D/A¿C-1¿MP
  3. Mar 7, 2025FDARecall: PROLENE BLU 18IN(45CM) USP6-0(M0.7) S/A P-1 PRM
  4. Mar 7, 2025FDARecall: ETHIBOND EXCEL GRN 36IN(90CM) USP2-0(M3) D/A MH
  5. Mar 7, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  6. Mar 20, 2025FDAFDA drug approval: Tremfya
  7. Mar 21, 2025FDAFDA drug approval: Prezcobix
  8. Mar 24, 2025CongressDisclosed sale of JNJ — reported range $100,001 - $250,000
  9. Mar 28, 2025FDAFDA device clearance: Synthes Graphic Case & Tray System
  10. Mar 31, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  11. Apr 1, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  12. Apr 8, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  13. Apr 9, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  14. Apr 10, 2025FDAFDA drug approval: Darzalex
  15. Apr 21, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  16. Apr 22, 2025FDARecall: Endopath Echelon Vascular White Reload for Advanced Placement Tip (35mm, 4 row); Product code VASECR35
  17. Apr 24, 2025FDAFDA device clearance: MENTOR™ PliaForm™ Breast Tissue Expander w/ Suture Tabs
  18. Apr 29, 2025FDAFDA drug approval: Imaavy
  19. Apr 29, 2025Congress · 1 personMembers of Congress: 2 sales
  20. May 2, 2025FDAFDA device clearance: Shockwave CS Guide Catheter
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 3 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

How this filing works

Explore the data

Common questions

Which Johnson & Johnson (JNJ) insider traded, and how much?

Marillyn A Hewson, Director at Johnson & Johnson, reported a grant / award of 75.26 units. At $166.10.

When did it happen, and when was it made public?

Traded: Mar 4, 2025. Filed: Mar 13, 2026. That is 374 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Johnson & Johnson recently?

For Johnson & Johnson, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 3 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days. They are listed on the JNJ page.

Does this mean JNJ stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Johnson & Johnson

Everything OQRO holds on this company is on its JNJ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data